BGNE BeiGene Ltd.

170.36
+2.51  (+2%)
Previous Close 167.85
Open 169
Price To Book 8.14
Market Cap 13,126,935,965
Shares 77,054,097
Volume 350,793
Short Ratio
Av. Daily Volume 457,541
Stock charts supplied by TradingView

NewsSee all news

  1. EUSA Pharma and BeiGene Announce Exclusive Development and Commercialization Agreement for SYLVANT® and QARZIBA®▼ in Greater China

    - SYLVANT® and QARZIBA®▼ recently listed for fast-track approval in China – - Expands EUSA's global product offering; broadens BeiGene's portfolio – HEMEL HEMPSTEAD, England and CAMBRIDGE, Mass. and BEIJING, China,

  2. BeiGene to Present at the 38th Annual J.P. Morgan Healthcare Conference

    CAMBRIDGE, Mass. and BEIJING, China, Jan. 08, 2020 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ:BGNE, HKEX: 06160)), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative

  3. Leap Therapeutics and BeiGene Announce Exclusive Option and License Agreement for DKN-01 and Leap Announces $27 Million Equity Financing

    CAMBRIDGE, Mass. and BEIJING, Jan. 3, 2020 /PRNewswire/ -- Leap Therapeutics, Inc. (NASDAQ:LPTX), a biotechnology company developing targeted immuno-oncology therapeutics, and BeiGene, Ltd. (NASDAQ:BGNE, HKEX: 06160)), a

  4. BeiGene Announces Closing of Amgen Global Strategic Oncology Collaboration and Equity Investment

    Amgen Completes Purchase of Approximately $2.8 Billion of BeiGene SharesAnthony C. Hooper, Former Executive Vice President of Global Commercial Operations at Amgen, Joins BeiGene Board of Directors CAMBRIDGE, Mass. and

  5. China National Medical Products Administration Approves BeiGene's Tislelizumab for Patients with Classical Hodgkin's Lymphoma Who Have Received at Least Two Prior Therapies

    Second BeiGene-discovered drug to receive regulatory approval, first in ChinaTislelizumab is an anti–PD-1 antibody specifically designed to minimize binding to FcγR on macrophages BEIJING, China and CAMBRIDGE, Mass.,

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 3 enrolment completed.
Tislelizumab
Hepatocellular carcinoma (HCC)
Will regulatory discussions based on preliminary results in 2020.
Pamiparib (BGB-290)
Ovarian Cancers or Triple-Negative Breast Cancer
Phase 3 presentation at ASH December 8, 2019 noted ORR was 92.7%; PR 78.9%. Top-line data due 2020.
Zanubrutinib (BGB-3111) - SEQUOIA
First-line chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL)
Phase 1b data presented at ICML June 20, 2019 noted ORR 72-100%. Phase 2 trial is ongoing.
Zanubrutinib and Obinutuzumab
Relapsed/Refractory (R/R) Follicular Lymphoma (FL)
Phase 3 trial to be initiated 1H 2018.
Pamiparib (BGB-290)
Solid tumors - cancer
Phase 2 pivotial China trial initiation announced July 5, 2017.
BGB-A317
Urothelial cancer (UC) - bladder cancer
Phase 2 pivotal updated data presented at EHA June 2019 noted 87% ORR (63% CR).
Tislelizumab - BGB-A317
Relapsed or refractory classical Hodgkin lymphoma (cHL)
FDA Approval announced November 14, 2019.
Zanubrutinib (BGB-3111)
Relapsed or refractory mantle cell lymphoma (MCL)
Phase 3 top-line data did not meet primary endpoint - December 16, 2019.
Zanubrutinib (BGB-3111) - ASPEN
Waldenström’s macroglobulinemia
Phase 3 enrolment to be completed 1H 2020.
Tislelizumab - BGB-A317
Esophageal Squamous Cell Carcinoma (ESCC)
Phase 2 regulatory discussions to take place 2019 or early 2020.
Tislelizumab
Hepatocellular carcinoma (HCC) - second-line
Phase 3 trial initiation announced July 24, 2018.
Pamiparib (BGB-290)
Gastric Cancer
Phase 3 data due 2020.
Pamiparib (BGB-290)
Maintenance Therapy Ovarian Cancer
Phase 3 enrolment to be completed in 2019 or early 2020.
Tislelizumab
Non-small cell lung cancer (NSCLC)
Phase 3 data due 2020.
Tislelizumab
Squamous non-small cell lung cancer (NSCLC)
Phase 1/2 data presented at SNO November 16, 2018 noted 2/15 partial responses.
Pamiparib (BGB-290)
Glioblastoma (GBM)
Phase 3 enrolment to be completed 2020.
Zanubrutinib (BGB-3111) vs Ibrutinib - ALPINE
Refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL)
Phase 1 data noted ORR 23.5% - December 13, 2019.
Sitravatinib and tislelizumab
Ovarian cancer
Phase 3 commencement of enrolment announced December 17, 2018.
Tislelizumab
Gastric Cancer
Phase 1/2 updated data at ASH 2019 noted ORR 95.9% (118/123); the PR 73.2% (90/123).
Zanubrutinib (BGB-3111)
Waldenström’s macroglobulinemia
Phase 2 trial enrolment to be completed 2020.
Zanubrutinib (BGB-3111) - MAGNOLIA
Marginal Zone Lymphoma
Phase 3 trial ongoing.
Tislelizumab
Nasopharyngeal cancer
Phase 3 trial ongoing.
Zanubrutinib plus rituximab
Mantle cell lymphoma (MCL) - front-line

Latest News

  1. EUSA Pharma and BeiGene Announce Exclusive Development and Commercialization Agreement for SYLVANT® and QARZIBA®▼ in Greater China

    - SYLVANT® and QARZIBA®▼ recently listed for fast-track approval in China – - Expands EUSA's global product offering; broadens BeiGene's portfolio – HEMEL HEMPSTEAD, England and CAMBRIDGE, Mass. and BEIJING, China,

  2. BeiGene to Present at the 38th Annual J.P. Morgan Healthcare Conference

    CAMBRIDGE, Mass. and BEIJING, China, Jan. 08, 2020 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ:BGNE, HKEX: 06160)), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative

  3. Leap Therapeutics and BeiGene Announce Exclusive Option and License Agreement for DKN-01 and Leap Announces $27 Million Equity Financing

    CAMBRIDGE, Mass. and BEIJING, Jan. 3, 2020 /PRNewswire/ -- Leap Therapeutics, Inc. (NASDAQ:LPTX), a biotechnology company developing targeted immuno-oncology therapeutics, and BeiGene, Ltd. (NASDAQ:BGNE, HKEX: 06160)), a

  4. BeiGene Announces Closing of Amgen Global Strategic Oncology Collaboration and Equity Investment

    Amgen Completes Purchase of Approximately $2.8 Billion of BeiGene SharesAnthony C. Hooper, Former Executive Vice President of Global Commercial Operations at Amgen, Joins BeiGene Board of Directors CAMBRIDGE, Mass. and

  5. China National Medical Products Administration Approves BeiGene's Tislelizumab for Patients with Classical Hodgkin's Lymphoma Who Have Received at Least Two Prior Therapies

    Second BeiGene-discovered drug to receive regulatory approval, first in ChinaTislelizumab is an anti–PD-1 antibody specifically designed to minimize binding to FcγR on macrophages BEIJING, China and CAMBRIDGE, Mass.,

  6. BeiGene Announces Acceptance of a Supplemental New Drug Application in China for REVLIMID® in Relapsed or Refractory Indolent Lymphoma

    BEIJING, China and CAMBRIDGE, Mass., Dec. 22, 2019 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ:BGNE, HKEX: 06160)), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative

  7. BeiGene Announces Results of Phase 3 ASPEN Trial of Zanubrutinib Compared to Ibrutinib for the Treatment of Patients with Waldenström's Macroglobulinemia

    - Primary Endpoint of Statistical Superiority Related to Deep Response (VGPR or Better) Was Not Met; However, Zanubrutinib Demonstrated More Frequent VGPRs (28.4% vs.19.2% in Overall Population)- Zanubrutinib

  8. BeiGene Announces Clinical Data on BRUKINSA™ (Zanubrutinib) at the 61st American Society of Hematology (ASH) Annual Meeting

    Oral presentations on data from two clinical trials in chronic lymphocytic leukemia or small lymphocytic lymphoma Poster presentation on data from clinical trial of BRUKINSA combined with tislelizumab in B-cell

  9. BeiGene to Present at the 31st Annual Piper Jaffray Healthcare Conference

    CAMBRIDGE, Mass. and BEIJING, China, Nov. 26, 2019 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ:BGNE, HKEX: 06160)), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative

  10. BeiGene Announces Clinical Data on Tislelizumab Presented at European Society for Medical Oncology (ESMO) Asia 2019 Congress

    CAMBRIDGE, Mass. and BEIJING, China, Nov. 23, 2019 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ:BGNE, HKEX: 06160)), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative

  11. U.S. FDA Grants BeiGene's BRUKINSA™ (zanubrutinib) Accelerated Approval to Treat Adult Patients with Mantle Cell Lymphoma Who Received at Least One Prior Therapy

    - This marks the first FDA approval for BeiGene - 84% of patients taking BRUKINSA achieved an overall response1 - BRUKINSA is the only FDA-approved BTK inhibitor shown to deliver 100% median occupancy in peripheral

  12. BeiGene Reports Third Quarter 2019 Financial Results

    CAMBRIDGE, Mass. and BEIJING, China, Nov. 12, 2019 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ:BGNE, HKEX: 06160)), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative

  13. BeiGene Announces Clinical Data on Zanubrutinib to Be Presented at the 61st American Society of Hematology Annual Meeting

    CAMBRIDGE, Mass. and BEIJING, China, Nov. 06, 2019 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ:BGNE, HKEX: 06160)), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative

  14. Seattle Genetics and BeiGene Announce Global License Agreement for Advanced Preclinical Product Candidate

    -BeiGene and Seattle Genetics to Collaborate on Global Clinical Trials- Seattle Genetics, Inc. (NASDAQ:SGEN) and BeiGene, Ltd. (NASDAQ:BGNE, HKEX: 06160)) today announced that the companies have entered into a license

  15. BeiGene Announces Global Strategic Oncology Collaboration with Amgen

    • Companies to Collaborate on the Commercialization of XGEVA® (denosumab), KYPROLIS® (carfilzomib), and BLINCYTO® (blinatumomab) in China  • Companies to Jointly Develop 20 Amgen Oncology Pipeline Assets, with BeiGene

  16. Bragar Eagel & Squire, P.C. Is Investigating Tandy Leather Factory, ADTRAN, BeiGene, and Altria Group on Behalf of Stockholders and Encourages Investors to Contact the Firm

    NEW YORK, Oct. 01, 2019 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C. is investigating potential claims against Tandy Leather Factory, Inc. (NASDAQ:TLF), ADTRAN, Inc. (NASDAQ:ADTN), BeiGene, Ltd. (NASDAQ:BGNE),

  17. BGNE INVESTOR REMINDER: Hagens Berman Reminds BeiGene, Ltd. (BGNE) Investors of Ongoing Investigation of Possible Securities Fraud

    SAN FRANCISCO, Sept. 30, 2019 (GLOBE NEWSWIRE) -- Hagens Berman reminds BGNE investors that it has launched an investigation into BeiGene, Ltd. (NASDAQ:BGNE) regarding possible violations of Federal securities laws,

  18. BeiGene Announces Clinical Data on Tislelizumab and Pamiparib Presented at the European Society for Medical Oncology (ESMO) Congress 2019

    CAMBRIDGE, Mass. and BEIJING, China, Sept. 30, 2019 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ:BGNE, HKEX: 06160)), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative

  19. BeiGene Announces Clinical Data on Tislelizumab and Pamiparib to Be Presented at the European Society for Medical Oncology (ESMO) Congress 2019

    CAMBRIDGE, Mass. and BEIJING, China, Sept. 26, 2019 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ:BGNE, HKEX: 06160)), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative

  20. BGNE INVESTIGATION REMINDER: Hagens Berman Reminds BeiGene, Ltd. (BGNE) Investors of Ongoing Investigation of Possible Securities Fraud

    SAN FRANCISCO, Sept. 23, 2019 (GLOBE NEWSWIRE) -- Hagens Berman reminds BGNE investors that it has launched an investigation into BeiGene, Ltd. (NASDAQ:BGNE) regarding possible violations of Federal securities laws,

  21. BeiGene Announces Clinical Results on Tislelizumab Presented at the 22nd Annual Meeting of the Chinese Society of Clinical Oncology (CSCO)

    BEIJING, China and CAMBRIDGE, Mass., Sept. 22, 2019 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ:BGNE, HKEX: 06160)), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative

  22. BGNE SHAREHOLDER ALERT: Hagens Berman Reminds Investors in BeiGene, Ltd. (BGNE) of Ongoing Investigation of Possible Securities Fraud

    SAN FRANCISCO, Sept. 17, 2019 (GLOBE NEWSWIRE) -- Hagens Berman reminds BGNE investors that it has launched an investigation into BeiGene, Ltd. (NASDAQ:BGNE) regarding possible violations of Federal securities laws,

  23. Glancy Prongay & Murray LLP Continues Its Investigation on Behalf of BeiGene, Ltd. Investors

    Glancy Prongay & Murray LLP ("GPM")

  24. INVESTOR ALERT: Law Offices of Howard G. Smith Continues Its Investigation on Behalf of BeiGene, Ltd. Investors (BGNE)

    Law Offices of Howard G. Smith continues its investigation on behalf of BeiGene, Ltd. ("BeiGene" or the "Company") (NASDAQ: BGNE) investors concerning the Company and its officers' possible violations of federal securities laws.

  25. Bragar Eagel & Squire, P.C. is Investigating BeiGene, Ltd. (NASDAQ: BGNE) on Behalf of BeiGene Stockholders and Encourages BeiGene Investors to Contact the Firm

    Bragar Eagel & Squire, P.C. is investigating potential claims against BeiGene, Ltd. (NASDAQ:BGNE) on behalf of BeiGene stockholders. Our investigation concerns whether BeiGene has violated the federal securities

  26. Glancy Prongay & Murray LLP Announces Investigation on Behalf of BeiGene, Ltd. Investors

    Glancy Prongay & Murray LLP ("GPM")

  27. SHAREHOLDER ALERT: Hagens Berman Notifies Investors in BeiGene, Ltd. (BGNE) of Securities Fraud Investigation

    SAN FRANCISCO, Sept. 12, 2019 /PRNewswire/ -- Hagens Berman has launched an investigation into BeiGene, Ltd. (NASDAQ:BGNE) regarding possible violations of Federal securities laws, and is urging investors to find out

  28. INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation on Behalf of BeiGene, Ltd. Investors (BGNE)

    Law Offices of Howard G. Smith announces an investigation on behalf of BeiGene, Ltd. ("BeiGene" or the "Company") (NASDAQ: BGNE) investors concerning the Company and its officers' possible violations of federal securities laws.

  29. BeiGene Announces Clinical Data to Be Presented at the Annual Meeting of the Chinese Society of Clinical Oncology (CSCO)

    BEIJING, China and CAMBRIDGE, Mass., Sept. 11, 2019 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ:BGNE, HKEX: 06160)), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative

  30. BeiGene to Hold Conference Call and Webcast on September 8, 2019 at 7:00 p.m. ET to Provide Corporate Update

    CAMBRIDGE, Mass. and BEIJING, China, Sept. 08, 2019 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ:BGNE, HKEX: 06160)), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative

  31. BeiGene to Present at the Morgan Stanley 17th Annual Global Healthcare Conference

    CAMBRIDGE, Mass. and BEIJING, China, Sept. 03, 2019 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ:BGNE, HKEX: 06160)), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative